ArticleProbiotics and antimicrobial proteins2026
Canine Microencapsulated Probiotic Formulations Modulate Immunity and Improve Acute Diarrhea in Dogs.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Randomised controlled trial finds no evidence that a synbiotic improves health in assistance dog puppies.The Veterinary record · 2026Article
- Functional Effects ofInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Host-derived probiotic strains offer an effective alternative to antibiotics for improving animal gastrointestinal health. In this study, two probiotic strains-Lactiplantibacillus plantarum TUCO-16 and Lacticaseibacillus rhamnosus TUCO-17-isolated initially from canine colostrum and milk, were scaled up and formulated with oligosaccharides into freeze-dried preparations. These formulations were evaluated in vitro using canine or human cell models to assess cytotoxicity, adhesion capacity, immune-related gene expression, reactive oxygen species (ROS) production, and paracellular permeability. The strains demonstrated high adhesion of up to 92% (p < 0.001), no cytotoxic effects, and induced significant (p < 0.0001) expression of both pro- and anti-inflammatory cytokines. They also stimulated the expression of mucins and tight junction proteins in epithelial cells up to increases of 414-fold and 21-fold (p < 0.0001), respectively. In addition, the formulations enhanced ROS production in macrophages (p < 0.0001) and maintained or reduced epithelial permeability (p < 0.0001). An in vivo trial in dogs with acute diarrhea confirmed the safety of the formulations. It showed improvement in stool consistency at the end of treatment without affecting frequency, contrasting with the effects of metronidazole. Overall, the results support using these host-specific probiotics as immunomodulatory agents that enhance intestinal barrier integrity and offer a safe, antibiotic-free alternative for managing acute diarrhea in dogs.
Indexed as
Identifiers
40782189What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.